AI Summary
- Products labelled "cannabidiol" often have incorrect CBD levels, contaminants, or undisclosed THC, risking efficacy and safety for patients.
- Clinicians must verify product composition, source, and lab testing to guide dosing and avoid adverse interactions with other medications.
- Greater regulation, standardised testing, and clearer labelling are urgently needed to protect patients and enable evidence-based CBD prescribing.
Braz J Psychiatry. 2026 Sep 18. doi: 10.47626/1516-4446-2026-5187. Online ahead of print.
NO ABSTRACT
PMID:42758935 | DOI:10.47626/1516-4446-2026-5187
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
Save as PDF
⭐ My Revision List

